ArticleInfectious diseases and therapy2026
Lessons Learned: Defining the Right Specifications for Diagnostics in Outbreak Situations.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic significantly changed the development and use of infectious disease diagnostics, emphasizing the need for rapid implementation, access equity, and revealing challenges in evaluation and licensing from unclear guidelines.
methodsAn international expert panel was convened by Roche Diagnostics, Fraunhofer Institute for Translational Medicine and Pharmacology (Immunology, Infection and Pandemic Research division), and Ludwig Maximilians University to address these challenges. The panel aimed to develop parameters for designing minimal viable products and consequence-centered diagnostic strategies, focusing on the broader implications of test results for public health interventions and disease control rather than individual test performance.
resultsKey findings included the need to tailor target product profiles to outbreak scenarios, considering socioeconomic factors and outbreak phases. Prioritizing rapid, cost-effective, and widely accessible tests, even at the expense of lower sensitivity was highlighted. Using such tools was effective during the SARS-CoV-2 pandemic because they were wider-reaching and identified more cases, especially in low-/middle-income countries where highly sensitive molecular tests had limited availability.
conclusionModeling different testing strategies allows outbreak control programs to quantify the impact of trade-offs between accessibility, affordability, and speed of diagnosis in different outbreak settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.